Abhinav Singla, MD
Addiction Medicine · Joliet, ILNPI 1659300796
Payments from drug & device makers
Across 1,899 payments — averaging $60.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$95K
- Novo Nordisk$2K
- Otsuka America Pharmaceutical, Inc.$1K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $13K from 54 others
What the payments were for
- Consulting fees$3500%
- Speaking & faculty fees$87,17876%
- Food & beverage$27,51524%
- Education$3480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$115,390 in reported general payments places this provider in the 95th percentile of 47 addiction medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 206 | $244,644 |
| OzempicSemaglutide | 127 | $154,117 |
| ZenpepLipase/Protease/Amylase | 30 | $116,982 |
| VraylarCariprazine Hcl | 45 | $83,123 |
| EliquisApixaban | 66 | $59,989 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 397 | $47,374 |
| FarxigaDapagliflozin Propanediol | 54 | $45,224 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 55 | $42,374 |
| TrulicityDulaglutide | 37 | $34,925 |
| UbrelvyUbrogepant | 28 | $33,733 |
| LinzessLinaclotide | 23 | $23,396 |
| JardianceEmpagliflozin | 21 | $22,528 |
| RexultiBrexpiprazole | 15 | $21,992 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 52 | $18,725 |
| QuliptaAtogepant | 14 | $18,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,356 | $279,569243 claims |
| AbbVieVraylar, Ubrelvy, Linzess, Qulipta | $94,515 | $158,630110 claims |
| Novo NordiskOzempic | $1,553 | $154,117127 claims |
| Aimmune Therapeutics, Inc.Zenpep | $622 | $116,98230 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,394 | $98,853144 claims |
| PfizerEliquis, Nurtec Odt | $985 | $72,67878 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine | $49 | $50,619409 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $645 | $28,61132 claims |
| MerckJanuvia, Belsomra | $133 | $23,43728 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,461 | $21,99215 claims |
| Orexo US, Inc.Zubsolv | $416 | $18,72552 claims |
| Johnson & JohnsonXarelto | $327 | $15,00417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 47 addiction medicine providers in Illinois.
Other addiction medicine in Joliet
- Roueen RafeyanChicago$14M
- Lucy IbrahimRomeoville$3M
- Leonard SpishakoffRomeoville$11K
- Phillip HeldingHinsdale$8K
- Adeyemi FatokiOttawa$8K
- Michael BlainEldorado$6K
- Albert TanlimWatseka$5K
- Francesco TaniChicago$4K
- Neha DattaOrland Park$4K
- Michael RachmanSchaumburg$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.